Healthtech Startups

Kite develops CAR T-cell therapies that engineer a patient's own immune cells to target and destroy cancer cells. The company focuses on cell therapy treatments for cancers such as diffuse large B-cell lymphoma.

2 investors

Kivo is a document management system for life sciences organizations that ensures GxP compliance through 21 CFR Part 11 e-signatures, access controls, and audit trails. The platform integrates DocuSign and Microsoft Office to support collaborative authoring, approval workflows, training assignments, and real-time compliance reporting.

2 investors

FODZYME develops an enzyme powder supplement that breaks down FODMAPs in food, particularly fructans found in garlic, onions, and wheat, for people with digestive sensitivities. The product targets individuals who need to manage FODMAP intolerance to improve their diet flexibility and quality of life.

2 investors

KIYATEC develops 3D Predict, a tumor-specific testing platform that uses patient-derived tumor cells to predict how individual cancers respond to therapies. It serves oncologists and cancer patients in the precision oncology and diagnostics space.

2 investors

Klarify is a mental health platform built by engineers, researchers, and designers who focus on therapy outcomes.

2 investors

KLOwen Orthodontics builds a full custom digital orthodontic system, including a custom bracket portfolio, cloud-based treatment planning software, a digital lab, and 3D-printed indirect bonding trays. It serves licensed orthodontists, aiming to reduce treatment time and the number of patient appointments.

2 investors

Knipper provides multi-modal pharmaceutical fulfillment and dispensing services, including patient access solutions, pharmacy fulfillment, samples management, and third-party logistics for pharma companies. Its offerings, marketed under CareTria, aim to speed the path from prescription order to patient therapy and support prescriber engagement.

2 investors

Knopp Biosciences is a privately held company that manages a portfolio of future milestone payments and product royalties from drug pipelines it sold or spun off in 2022. Its Kv7 small-molecule platform for epilepsy and hyperexcitability disorders was acquired by Biohaven Pharmaceuticals, and its dexpramipexole platform was spun off to Areteia Therapeutics.

2 investors

2 investors

Kodda provides structured health and lifestyle programs designed and guided by professionals to help users achieve sustainable personal wellness improvements.

2 investors

Kometa Bio develops dental surgical devices, specifically the Smart Dentin Grinder, which processes autologous dentin for bone augmentation procedures in dental practice.

2 investors

Kovina develops first-in-class small molecule antiviral drugs to treat HPV-induced cancers and premalignant infections such as cervical and anal dysplasia. The company aims to offer non-surgical treatment options for patients living with HPV.

2 investors

Krystal Biotech discovers, develops, and commercializes genetic medicines, including gene therapy programs for rare diseases such as dermatological conditions. The company operates across the US, Europe, and Japan.

2 investors

KuartisMED develops AI-enabled solutions for newborn health monitoring and clinical decision support, particularly for premature babies. The platform is designed to assist physicians with clinical insights and provide information to parents.

2 investors

Kuros Biosciences is a Swiss biotech company developing biologic technologies for bone healing and bone grafts, primarily for spine, extremities, and pelvis surgical applications. Originally a spin-off of the Swiss Federal Institute of Technology in Zurich, it is publicly listed on the SIX Swiss Stock Exchange and operates in Switzerland, the Netherlands, and the USA.

2 investors

KYMIRA develops advanced smart textile technologies embedded directly into clothing for continuous health monitoring and performance support. The company serves elite sport, healthcare, defense, and consumer markets with clinically validated infrared, filtration, and biomedical sensing technologies.

2 investors

Kynexis is a clinical-stage biotech developing KYN-5356, an oral small-molecule KAT-II inhibitor targeting the kynurenine pathway to improve cognition in neurological diseases. Its lead program is in a Phase 2 trial for cognitive impairment associated with schizophrenia (CIAS), with expansion planned into Alzheimer's disease.

2 investors

Kypha develops clinical diagnostic tests for immune system biomarkers, particularly complement activity markers, and provides solutions for real-time immune insights across therapeutic areas. The company serves biopharma firms, clinical laboratories, and medical institutions through a network of clinical collaborators and research partners.

2 investors

Kyron.bio is a biotechnology company focused on developing therapeutic drugs, with an in-house R&D and laboratory operation.

2 investors

L-Nutra develops fasting-mimicking technology and nutrition-based products designed to slow biological aging and treat age-related diseases. The company focuses on translating longevity research into consumer health interventions.

2 investors

LabCorp provides diagnostic testing services and clinical trial recruitment solutions that connect patient insights to drug development for healthcare providers.

2 investors

Laborie develops medical devices and solutions for women's health, including technologies to manage complications like postpartum hemorrhage.

2 investors

Labrador Systems develops robots for everyday assistance, applying sensor, processor, and algorithm technology from augmented reality and self-driving fields to build practical robots that support people in daily life.

2 investors

Lactiga is a biotechnology company developing mucosal antibody therapies based on secretory IgA antibodies derived from human breastmilk. Its platform targets conditions such as chronic respiratory disorders, gut inflammation, and immune deficiencies through mucosal immunotherapy.

2 investors